Dear
Maria
Please
find attached a copy of my PowerPoint presentation for the upcoming meeting on
16th November 2004.
Please
can you confirm receipt.
With
kind regards
Colin
Garner
Professor Colin Garner BPharm PhD DSc
FRCPath
Chief Executive
Officer
-----------------------------------
Xceleron Ltd
York Biocentre
Innovation Way
Heslington
York YO10 5NY
United Kingdom
Switchboard: +44(0)1904
561561
Direct line: +44(0)1904
561568
FAX:
+44(0)1904 561560
Email: colin.garner@xceleron.co.uk
Why not visit our Web
site
Important
Notice:
The information contained in this
message may include privileged, proprietary or confidential information. Please treat it with the same respect
that you would expect for your own information. If you have received it in error, we
apologise, and ask that you contact the sender immediately and erase it from
your computer. Thank you for your
co-operation.
-----Original
Message-----
From: Walsh, Maria
R [mailto:WALSH@cder.fda.gov]
Sent: 01 November 2004 14:04
To: 'Gill Pilgrim'; Walsh, Maria
R
Cc: Colin Garner
Subject: RE: Docket No
2004N-0432
Dear
Gill,
Just a
reminder...if Professor Garner plans to use an electronic presentation at
the November 16, 2004 public meeting (e.g. PowerPoint slides), the final
presentation must be submitted to me by close of business November 2,
2004.
Thanks.
Maria
-----Original
Message-----
From: Gill Pilgrim
[mailto:gill.pilgrim@xceleron.co.uk]
Sent: Monday, November 01, 2004 5:52
AM
To:
WALSH@cder.fda.gov
Cc: Colin
Garner
Subject: FW: Docket No
2004N-0432
Dear
Maria
Please find attached
edit by Professor Colin Garner to his submission for presentation at the
November 16th RDRC public meeting during the 2.45 - 4.00pm public presentation
period.
With kind
regards.
Gill
-------------------------------------------------------
Gill Pilgrim
Administrative
Secretary/Archivist
------------------------------------------------------
Xceleron Ltd
York
Biocentre
Innovation Way
Heslington
York
YO10 5NY
United
Kingdom
Tel No:
+44(0)1904 561561
Fax No: +44(0)1904 561560
Email: gill.pilgrim@xceleron.co.uk
Visit our Web site at
http://www.xceleron.co.uk
Important Notice
The information contained in
this message may include privileged, proprietary or confidential
information. Please treat it with the same respect that you would expect
for your own information. If you have received it in error, we apologise,
and ask that you contact the sender immediately and erase it from your
computer. Thank you for your co-operation.
From:
Colin Garner
Sent: 01 November
2004 09:04
To: Gill
Pilgrim
Subject: RE: Docket No
2004N-0432
Please see
attached for edits. I think I sent my original to the wrong address.
However please send this to Maria Walsh.
Many
thanks
Colin
From:
Gill Pilgrim
Sent: 01 November
2004 08:39
To: Colin
Garner
Subject: FW: Docket No
2004N-0432
Importance:
High
Colin
Do you
have any edits re your presentation, if so they must be in by end of
today.
Gill
-------------------------------------------------------
Gill Pilgrim
Administrative
Secretary/Archivist
------------------------------------------------------
Xceleron
Ltd
Innovation Way
Heslington
YO10 5NY
Tel No:
+44(0)1904 561561
Fax No: +44(0)1904 561560
Email: gill.pilgrim@xceleron.co.uk
Visit our Web site at
http://www.xceleron.co.uk
Important Notice
The information contained in
this message may include privileged, proprietary or confidential
information. Please treat it with the same respect that you would expect
for your own information. If you have received it in error, we apologise,
and ask that you contact the sender immediately and erase it from your
computer. Thank you for your co-operation.
From:
Colin Garner
Sent: 26 October
2004 18:14
To: Gill Pilgrim;
June Garner; Andrew Davidson
Subject: FW: Docket No
2004N-0432
Importance:
High
Professor Colin
Garner BPharm PhD DSc FRCPath
Chief Executive
Officer
-----------------------------------
Xceleron
Ltd
York
Biocentre
Innovation
Way
Heslington
York YO10
5NY
United
Kingdom
Switchboard: +44(0)1904
561561
Direct line:
+44(0)1904 561568
FAX:
+44(0)1904 561560
Email: colin.garner@xceleron.co.uk
Why not visit our
Web site
Important
Notice:
The information
contained in this message may include privileged, proprietary or confidential
information. Please treat it with the same respect that you would expect
for your own information. If you have received it in error, we apologise,
and ask that you contact the sender immediately and erase it from your
computer. Thank you for your co-operation.
-----Original
Message-----
From: Walsh, Maria
R [mailto:WALSH@cder.fda.gov]
Sent: 26 October 2004 18:06
To:
'Colin.Garner@xceleron.co.uk'
Subject: FW: Docket No
2004N-0432
Importance:
High
Dr.
Garner,
You are
scheduled to present at the November 16th RDRC public meeting during the 2:45 -
4:00 pm public presentation
period. Your name will appear on the agenda as follows:
Colin Garner, PhD, DSc, FRCPath, CEO,
Xceleron Ltd.,
Please
let me know if you have any edits by close of business November 1,
2004.
Thank
you.
Maria
Maria
R. Walsh, RN, MS
Project
Management Officer
FDA/CDER/OND
Office
of Drug Evaluation III Immediate Office (HFD-103)
5600
Phone:
(301) 827-3139
Fax:
(301) 480-3761
e-mail:
walsh@cder.fda.gov
-----Original
Message-----
From: Colin Garner
[mailto:Colin.Garner@xceleron.co.uk]
Sent: Wednesday, October 13, 2004 8:31
AM
To:
'fdadockets@oc.fda.gov'
Subject: Docket No 2004N-0432
Importance: High
<<21 CFR Part
361 submission VO1 Garner Xceleron 16 November 2004.doc>>
Please find attached a
request to attend
and to present
at
the Public Meeting
concerning 21 CFR Part 361 on 16th November
2004.
Could you kindly
acknowledge receipt of this email and let me know if my attendance will be
possible?
Yours sincerely
Professor Colin Garner
BPharm PhD DSc FRCPath
Chief
Executive Officer
-----------------------------------
Xceleron
Ltd
Innovation
Way
Heslington
Switchboard:
+44(0)1904 561561
Direct line:
+44(0)1904 561568
FAX:
+44(0)1904 561560
Email: colin.garner@xceleron.co.uk
Why not visit our Web
site
Important
Notice:
The information
contained in this message may include privileged, proprietary or confidential
information. Please treat it with the same respect that you would expect
for your own information. If you have received it in error, we apologise,
and ask that you contact the sender immediately and erase it from your
computer. Thank you for your co-operation.